December 2, 2009 - Apnex Medical, Inc., a private medical device company, announced that it has completed a second round of private equity financing totaling $14 million. The funds will be used to complete a clinical study and develop a second generation of its proprietary implantable technology designed to treat obstructive sleep apnea (OSA).
Participants in the financing include Domain Associates, New Enterprise Associates (NEA), Polaris Venture Partners and Michael Berman. The current board includes Robert Atkinson, CEO, and Michael Berman, Chairman, together with Brian Chee, John Nehra and Nimesh Shah representing Polaris, NEA and Domain, respectively. This financing brings the total investment in Apnex Medical to $30 million.
“We are very excited about the early results with the Apnex Hypoglossal Nerve Stimulation (HGNS™) System in our clinical study. Our technology really has the potential to change the lives of people suffering from OSA. This round of financing will allow us to finish our initial clinical study and get us that much closer to market,”... [PDF] Apnex Medical's Press Release -
Blog Archive
-
▼
2010
(38)
-
▼
April
(11)
- MicroLight : laser treats fibromyalgia
- Ferring Pharmaceuticals : Wake Up to Nocturia - St...
- Cephalon : Complete Response Letter for NUVIGIL fo...
- Arena Pharmaceuticals : Initiation of Phase 1 Clin...
- SOMAXON : FDA APPROVAL OF SILENOR® (DOXEPIN) FOR ...
- GE’s Virtual Sleep Lab Enables Sleep Apnea Testing...
- ImThera Medical Successfully Implants First Patien...
- Lupin : FDA tentative approval for Eszopiclone tab...
- Vantia Therapeutics' lead candidate VA106483 enter...
- ResMed : Next-Generation CPAP Series in Europe
- Apnex Medical : Additional $14 Million
-
▼
April
(11)
Thursday, April 1, 2010
Apnex Medical : Additional $14 Million
Libellés :
Apnex Medical,
obstructive sleep apnea